BNT162b2 (sold as Comirnaty® in EU and Switzerland)
The Pfizer-BioNTech (COMIRNATY) vaccine was 95 percent effective in preventing laboratory-confirmed infection with the virus that causes COVID-19 in persons who received two doses and had no signs of being previously infected, according to results from clinical studies in people ages 16 and older.
The Pfizer-BioNTech vaccine exhibited >90% efficacy in clinical trials in preventing laboratory-confirmed COVID-19 infection in children aged 5–15 years, and the immune response in children aged 5–15 years was at least as robust as the immune response in persons aged 16–25 years.
In clinical trials, the vaccine also had >90% efficacy in preventing COVID-19 among patients of all ages, genders, races, and ethnicities, as well as those with underlying medical disorders.
MORE INFORMATION:
Manufacturer: Pfizer, Inc., and BioNTech
Number of Shots: 2 shots, 21 days apart
Moderately or severely immunocompromised people ages 5 years and older should get an additional primary shot at least 28 days after their second shot.
Type of Vaccine: mRNA
